Peter Senter, PhD

Affiliate Professor of Bioengineering at Washington University

Speaker

Peter Senter joined Seagen in 1998 where he built and led the chemistry group that carrieed out research in cancer drug design, antibody-drug conjugate technologies for cancer therapy, and protein chemistry. Several of the molecules generated in Dr. Senter’s lab have entered clinical trials, and four have been approved: Adcetris, Padcev and Tivdak from Seagen, and Etopophos from BMS. Dr. Senter has authored more than 160 scientific publications and holds many issued patents. He received an A.B. in Biochemistry from the University of California, Berkeley, a Ph.D. in Chemistry from the University of Illinois, and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Göttingen, Germany. He serves as Senior Editor on Molecular Cancer Therapeutics and is an Affiliate Professor of Bioengineering at the University of Washington.